Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AIR DNase

Other · developed by Protalix

Phase 2 Most advanced trial (none active)
PLX Developer
2 Registered trials

What is AIR DNase?

AIR DNase is an inhaled deoxyribonuclease formulation studied in cystic fibrosis, a chronic respiratory disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Respiratory
Developer
Protalix (PLX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02722122 Phase 2 Cystic Fibrosis Unknown PLX
NCT02605590 Phase 1 Cystic Fibrosis (CF) Completed PLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cystic FibrosisCystic Fibrosis (CF)

More from Protalix

Follow PLX, the company behind AIR DNase

See PLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PLX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.